HIMS & HERS HEALTH (NYSE: HIMS) CLASS ACTION NOTICE: Berger Montague Encourages Investors With Substantial Losses To Contact The Firm By August 25, 2025

2025-07-28 05:15:58

(MENAFN- GlobeNewsWire - Nasdaq) PHILADELPHIA, July 28, 2025 (GLOBE NEWSWIRE) -- Berger Montague , a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. (“Hims & Hers” or the“Company”) ( NYSE: HIMS ). The firm is examining whether Hims & Hers, during the Class Period from April 29, 2025 through June 22, 2025 (the“Class Period”), violated federal securities laws by making false or misleading statements to investors.

Details of the Securities Fraud Investigation
On June 23, 2025, shares of Hims & Hers dropped more than 34% after Novo Nordisk revealed it terminated its partnership due to the Company's unauthorized marketing and sale of compounded semaglutide drugs. A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws.

Deadline to Act

Investors have until August 25, 2025 to seek appointment as lead plaintiff in the class action lawsuit. Lead plaintiffs help direct the case and advocate on behalf of other harmed investors.

If you are a Hims & Hers investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at ... or (215) 875-3015, or Caitlin Adorni at ... or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, and Toronto, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
...

Caitlin Adorni
Berger Montague
(267) 764-4865
...

MENAFN28072025004107003653ID1109853745

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.